Merrimack Pharmaceuticals Inc's Customers Performance

Name: Merrimack Pharmaceuticals Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

MACK

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


MACK's Source of Revenues		• List of MACK Customers

for the same period Merrimack Pharmaceuticals Inc

• List of MACK Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Merrimack Pharmaceuticals Inc's Comment on Sales, Marketing and Customers

News about Merrimack Pharmaceuticals Inc Contracts

Merrimack Pharmaceuticals, Inc. to Dissolve and Provide Cash Liquidating Dividend

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) has recently received stockholder approval for its Plan of Dissolution and subsequently declared a cash liquidating dividend of $15.10 per share. The company s Common Stock will continue trading on NASDAQ until May 17, 2024, after which it will be delisted. This article aims to ly present the factual information surrounding Merrimack s dissolution and dividend announcement.Merrimack Pharmaceuticals, Inc. has successfully gained stockholder approval for its Plan of Dissolution at a Special Meeting held recently in Cambridge, Massachusetts. The plan, which outlines the company s intent to dissolve, was overwhelmingly supported by stockholders. Following the approv...

Merrimack Pharmaceuticals Announces Plan of Dissolution, Stockholder Approval, and Cash Liquidating Dividend

In a recent announcement, Merrimack Pharmaceuticals, Inc. declared that its stockholders have overwhelmingly approved a Plan of Dissolution, marking a significant development for the company. Alongside this approval, the company s Board of Directors has declared a cash liquidating dividend of $15.10 per share. This article aims to outline the key facts surrounding these announcements and assess their potential impact on Merrimack Pharmaceuticals.1. Plan of Dissolution Approval:Merrimack Pharmaceuticals has achieved a major milestone as their stockholders have given resounding approval for the adoption of a Plan of Dissolution. This plan outlines the company s strategy for winding down its operations in an or...

MACK's Stock Performance relative to it's Customers

MACK's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Merrimack Pharmaceuticals Inc	218.66	0.00	200.46	117
SUBTOTAL	0.00	0.00	0.00	-

Sources: Merrimack Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Merrimack Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Merrimack Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.